LexDanaLexDanabeta
Inventor

Keting Chu

Inventor
Burlingame, CA, US

Overview

16→
Patents
1998–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 16 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides25%
A61KPreparations for medical, dental or toiletry purposes21%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12NMicroorganisms or enzymes16%
A01KAnimal husbandry8%
Y10TTechnical subjects covered by former us classification3%
B60WConjoint control of vehicle sub-units of different type or different function2%
G01CMeasuring distances, levels or bearings2%
G05DSystems for controlling or regulating non-electric variables2%
G08GTraffic control systems2%
PatentTitleYear
11,071,780Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab202110,976,745Systems and methods for autonomous vehicle path follower correction20218,088,383'Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies'20128,058,403'Antibodies to stromal cell-derived factor-1 polypeptides'20117,820,170'Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies'20107,776,564'Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use'20107,611,708'Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies'20097,445,780'Antagonistic anti-CD40 antibodies'20087,393,942'Nucleic acids encoding mutant forms of Fas ligand'20087,288,252'Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies'20076,544,523'Mutant forms of Fas ligand and uses thereof'20036,077,701'Ikk.beta. regulates transcription factors'20006,030,834'Human IKK-beta DNA constructs and cells'20005,962,652'Antibodies to protein, FAF1'19995,750,653'Protein, FAF1, which potentiates Fas-mediated apoptosis and uses thereof'19985,738,852'Methods of enhancing antigen-specific T cell responses'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–1999Patents assigned to UNIV CALIFORNIA (2)· patent assignee history
1998–2012Based in Burlingame, CA, US· patent location history
1998Based in Palo Alto, CA, US· patent location history
2000–2003Patents assigned to CHIRON CORP (3)· patent assignee history
2007–2012Patents assigned to NOVARTIS VACCINES & DIAGNOSTIC (6)· patent assignee history
2010–2011Patents assigned to FIVE PRIME THERAPEUTICS INC (2)· patent assignee history
2010–2011Based in Hillsborough, CA, US· patent location history
2011–2012Patents assigned to CHU KETING (2)· patent assignee history
2021Based in White Plains, NY, US· patent location history
2021Based in San Mateo, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
NOVARTIS VACCINES & DIAGNOSTIC62007–2012
CHIRON CORP32000–2003
CHU KETINGself22011–2012
FIVE PRIME THERAPEUTICS INC22010–2011
UNIV CALIFORNIA21998–1999
Locations
LocationPatentsSpan
Burlingame, California, US111998–2012
Hillsborough, California, US22010–2011
White Plains, New York, US12021
San Mateo, California, US12021
Palo Alto, California, US11998